In a patient currently taking escitalopram 20 mg and bupropion 150 mg who is depressed and agitated, what medication changes do you recommend?

Discontinue Wellbutrin and Optimize Escitalopram Dosing

In a patient on escitalopram 20 mg and bupropion 150 mg who remains depressed and agitated, you should discontinue the bupropion immediately, as it is activating and can worsen agitation, and consider augmentation strategies or switching to a different antidepressant if symptoms persist.

Rationale for Discontinuing Bupropion

The FDA label explicitly warns that bupropion should not be used in agitated patients 1. The drug is described as "activating" and can cause or worsen anxiety, agitation, panic attacks, insomnia, irritability, hostility, and aggressiveness 2, 1. Recent evidence confirms bupropion's stimulating properties can provoke anxiety, particularly at higher doses 3. Your patient's current dose of 150 mg is subtherapeutic (typical therapeutic range is 300-450 mg/day), yet they're already experiencing agitation—increasing the dose would likely worsen this symptom.

Immediate Management Steps

Step 1: Discontinue Bupropion

• Stop bupropion immediately given the agitation
• The activating effects contraindicate its use in this clinical scenario 2

Step 2: Assess Escitalopram Adequacy

Your patient is on escitalopram 20 mg, which is the standard maximum FDA-approved dose. However:

• Escitalopram can be dosed up to 40 mg/day in treatment-resistant cases 4, 5, 6
• The American College of Physicians recommends modifying treatment if inadequate response occurs within 6-8 weeks 7
• Monitor closely for emergence of agitation, as SSRIs themselves can cause jitteriness/anxiety syndrome, particularly escitalopram 7, 8

Step 3: Choose Your Next Strategy

Option A: Switch to Mirtazapine (Preferred for Agitated Depression)

• Mirtazapine is specifically indicated for agitated depression with insomnia 2
• Start at 7.5-15 mg at bedtime, titrate to 30 mg 2
• Provides sedation, reduces anxiety, and treats depression
• Recent data shows mirtazapine outperforms other antidepressants for insomnia and anxiety symptoms 9
• Well-tolerated with potent antidepressant effects 2

Option B: Switch to Vortioxetine

• Emerging evidence suggests vortioxetine may be particularly effective for patients with SSRI-induced jitteriness/anxiety syndrome 8
• Three case reports showed successful resolution of escitalopram-induced agitation/anxiety with vortioxetine 8
• Consider if patient has prominent anxiety with depression

Option C: Augmentation Strategy (if partial response to escitalopram)

• Add an atypical antipsychotic (risperidone 0.25-3 mg/day or quetiapine 12.5-200 mg twice daily) for agitation control 2
• Quetiapine is more sedating and may be preferable for agitated patients 2
• Consider trazodone 25-400 mg/day as a mood-stabilizing/anti-agitation agent 2

Option D: Switch to Duloxetine or Venlafaxine

• If switching within SNRI class, no clear superiority of one agent over another 10, 11
• However, these may also be activating and worsen agitation

Critical Monitoring Points

The FDA mandates close monitoring when initiating or changing antidepressants 7:

• Assess within 1-2 weeks of any medication change
• Monitor for worsening agitation, irritability, unusual behavior changes
• Watch for suicidal ideation (highest risk in first 1-2 months) 7
• SSRIs carry increased risk for suicide attempts compared to placebo 7

Common Pitfalls to Avoid

1. Don't increase bupropion dose - This will worsen agitation 2, 1
2. Don't add benzodiazepines long-term - While they treat acute agitation 12, regular use leads to tolerance, addiction, depression, and cognitive impairment; paradoxical agitation occurs in 10% of patients 2
3. Don't assume the current regimen just needs more time - If no response by 6-8 weeks, modification is indicated 7
4. Don't overlook non-pharmacologic interventions - Cognitive behavioral therapy shows equivalent efficacy to antidepressants and may be combined 7

Duration of Treatment

Once remission is achieved:

• Continue treatment for 4-9 months minimum for first episode 7
• For recurrent depression (≥2 episodes), consider longer-term maintenance 7